Treatment preferences in human papillomavirus-associated oropharyngeal cancer

Research output: Contribution to journalReview article

Abstract

The population of survivors with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is rising. The improved prognosis of this etiologic subset is reflected in new staging guidelines as well as ongoing deintensification trials aiming to preserve excellent survival while decreasing treatment-related toxicities. However, as staging criteria and treatment standards evolve in the era of transoral surgery and deintensification, little is known regarding the needs and treatment preferences of patients with HPV-OPSCC. Herein, the current knowledge regarding treatment preferences and priorities, quality of life and concerns among patients with HPV-OPSCC is reviewed.

Original languageEnglish (US)
Pages (from-to)2521-2530
Number of pages10
JournalFuture Oncology
Volume14
Issue number24
DOIs
StatePublished - Oct 1 2018

Fingerprint

Oropharyngeal Neoplasms
Squamous Cell Carcinoma
Patient Preference
Therapeutics
Survivors
Quality of Life
Guidelines
Survival
Population

Keywords

  • Head and neck cancer
  • Human papillomavirus
  • Oropharyngeal cancer
  • Otolaryngology
  • Patient preference
  • Radiotherapy
  • Robotic surgical procedures
  • Shared decision-making

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment preferences in human papillomavirus-associated oropharyngeal cancer. / Windon, Melina J.; D'Souza, Gypsyamber; Fakhry, Carole.

In: Future Oncology, Vol. 14, No. 24, 01.10.2018, p. 2521-2530.

Research output: Contribution to journalReview article

@article{24a239a030344083a827a83829b6cf83,
title = "Treatment preferences in human papillomavirus-associated oropharyngeal cancer",
abstract = "The population of survivors with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is rising. The improved prognosis of this etiologic subset is reflected in new staging guidelines as well as ongoing deintensification trials aiming to preserve excellent survival while decreasing treatment-related toxicities. However, as staging criteria and treatment standards evolve in the era of transoral surgery and deintensification, little is known regarding the needs and treatment preferences of patients with HPV-OPSCC. Herein, the current knowledge regarding treatment preferences and priorities, quality of life and concerns among patients with HPV-OPSCC is reviewed.",
keywords = "Head and neck cancer, Human papillomavirus, Oropharyngeal cancer, Otolaryngology, Patient preference, Radiotherapy, Robotic surgical procedures, Shared decision-making",
author = "Windon, {Melina J.} and Gypsyamber D'Souza and Carole Fakhry",
year = "2018",
month = "10",
day = "1",
doi = "10.2217/fon-2018-0063",
language = "English (US)",
volume = "14",
pages = "2521--2530",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "24",

}

TY - JOUR

T1 - Treatment preferences in human papillomavirus-associated oropharyngeal cancer

AU - Windon, Melina J.

AU - D'Souza, Gypsyamber

AU - Fakhry, Carole

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The population of survivors with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is rising. The improved prognosis of this etiologic subset is reflected in new staging guidelines as well as ongoing deintensification trials aiming to preserve excellent survival while decreasing treatment-related toxicities. However, as staging criteria and treatment standards evolve in the era of transoral surgery and deintensification, little is known regarding the needs and treatment preferences of patients with HPV-OPSCC. Herein, the current knowledge regarding treatment preferences and priorities, quality of life and concerns among patients with HPV-OPSCC is reviewed.

AB - The population of survivors with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is rising. The improved prognosis of this etiologic subset is reflected in new staging guidelines as well as ongoing deintensification trials aiming to preserve excellent survival while decreasing treatment-related toxicities. However, as staging criteria and treatment standards evolve in the era of transoral surgery and deintensification, little is known regarding the needs and treatment preferences of patients with HPV-OPSCC. Herein, the current knowledge regarding treatment preferences and priorities, quality of life and concerns among patients with HPV-OPSCC is reviewed.

KW - Head and neck cancer

KW - Human papillomavirus

KW - Oropharyngeal cancer

KW - Otolaryngology

KW - Patient preference

KW - Radiotherapy

KW - Robotic surgical procedures

KW - Shared decision-making

UR - http://www.scopus.com/inward/record.url?scp=85054424614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054424614&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0063

DO - 10.2217/fon-2018-0063

M3 - Review article

VL - 14

SP - 2521

EP - 2530

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 24

ER -